Document 3223
 DOCN  M94A3223
 TI    Effects on virological parameters of passive immunotherapy in AIDS
       patients. The PI Collaborative Study Group.
 DT    9412
 AU    Joubert L; Chevret S; Vittecoq D; Lefrere JJ; Hopital St-Antoine, Paris.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):125 (abstract no. PA0118). Unique
       Identifier : AIDSLINE ICA10/94369352
 AB    Eighty two CDC IV patients were evaluated in a double blind phase II
       trial and randomized between 2 groups: infusions of plasma rich in
       anti-p24 ab (HIV+P) or seronegative plasma (HIV-P). Each patient
       received infusion every 14 days over a one-year period and every 28 days
       beyond; p24 ag titer was quantified through monoclonal assay before and
       after immune complex dissociation (ICD). Anti-p24 ab titer was
       determined. Among the 46 patients positive for p24 ag before inclusion,
       p24 ag was found negative in 100% of treated patients in a median delay
       of 77 days, vs in 24% of controls in a median delay not reached at 1091
       days (p = 0.0001). The reapparance of a positive p24 ag was less
       frequent in treated patients (24%) than in controls (33%) (p = 0.31);
       among the 54 patients positive for ICD-p24, p24 ag was found negative in
       52% of treated patients in a median delay of 310 days vs 17% of controls
       (median not reached) (p = 0.006). Anti-p24 titers were negative or weak
       in most controls while treated patients had a titer variable according
       to both the ab titer of HIV+P and the ag of recipients. The negative p24
       ag without ICD observed in all treated patients reflects a complexation
       with ab; the results observed with ICD-ag assay suggest that this
       decrease of ag in treated group could also be due to a slower release of
       ag.
 DE    Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*MICROBIOLOGY/  *THERAPY
       Comparative Study  Double-Blind Method  Human  HIV
       Antibodies/TOXICITY/*THERAPEUTIC USE  HIV Core Protein
       p24/BLOOD/IMMUNOLOGY  *Immunotherapy, Adoptive/ADVERSE EFFECTS  CLINICAL
       TRIAL  CLINICAL TRIAL, PHASE II  MEETING ABSTRACT  RANDOMIZED CONTROLLED
       TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).